Walder Wyss has advised Vaderis Therapeutics. Vaderis Therapeutics, a Swiss clinical-stage biopharmaceutical company, has announced the completion of a USD 152 million Series B financing round....
Vaderis Therapeutics Closes USD 152 Million Series B Financing and Launches Phase 3 Study for Engasertib
Blockstrom AG Acquired by ista Swiss AG to Enhance Integrated Building Energy Solutions
Walder Wyss has advised ista as buyer; valfor has advised the shareholders of Blockstrom AG. Blockstrom AG, a company recognized for its pioneering work in digital...
UVC Partners Leads $24 Million Financing Round in Metafuels AG
Walder Wyss has advised UVC Partners as lead investor in the financing round of Metafuels AG. UVC Partners, headquartered in Berlin and Munich, has acted as...
TECregen Secures CHF 10 Million in Seed Round for Thymus Regeneration
Walder Wyss has advised TECregen. TECregen, a biotechnology company based in Basel, Switzerland, has raised CHF 10 million through a seed financing round. The company undertook...
Allegria Therapeutics Secures USD 5.1 Million in Seed Extension Funding
Walder Wyss has advised Allegria Therapeutics. Allegria Therapeutics, a biotechnology company based in Basel, Switzerland, has completed a seed extension funding round, raising USD 5.1 million....
AstraZeneca Acquires Swiss Biotech Firm SixPeaks Bio in USD 300 Million Deal
Walder Wyss has advised SixPeaks Bio AG and its shareholders (including Versant Ventures). Lenz & Staehelin has advised AstraZeneca. AstraZeneca has completed the acquisition of Swiss...
ZEISS Vision Care Acquires Minority Stake in Ocumeda to Expand European Teleophthalmology Platform
Walder Wyss has advised Fielmann Group and Ocumeda. ZEISS Vision Care has entered into a definitive agreement to acquire a 10% stake in Ocumeda AG at...
Nuclidium AG Secures CHF 79 Million in Series B Financing Round
VISCHER has advised Nuclidium AG. Walder Wyss has advised Angelini Ventures, Kurma Partners, and Wellington Partners as co-lead investors; Dentons has acted for Neva. Nuclidium AG,...
Mosanna Therapeutics Completes USD 80 Million Series A Funding Round
VISCHER has advised Mosanna Therapeutics AG; Walder Wyss advised EQT Life Sciences. Mosanna Therapeutics AG has successfully closed its USD 80 million Series A funding round....
KARL STORZ’s Acquisition Of Anklin
Walder Wyss advised the Anklin family on the deal. The Swiss company Anklin, based in Reinach, is now part of the KARL STORZ direct sales network,...
Prima Materia’s €10 Million Investment From Epiterna
VISCHER advises Epiterna with Prima Materia investment. Epiterna, a Swiss longevity company founded in 2022 by Alejandro Ocampo and Kevin Perez as a spin-off from Alejandro...
Medartis’ CHF 18 Million Acquisition of Additional Stake in KeriMedical
VISCHER advised Medartis on the deal. Medartis (SIX: MED), a Basel-based orthopedic company specializing in head and extremity surgery, recently signed an agreement with the private...